MID3: Mission Impossible or Model-Informed Drug Discovery and Development? Point-Counterpoint Discussions on Key Challenges.
Clicks: 253
ID: 84447
2020
MID3: Mission Impossible, or Model-Informed, Drug Discovery and Development? At the 2019 ASCPT annual meeting, point-counterpoint discussions were held on key challenges that limit, and future directions that enhance the adoption of MID3 across the drug discovery, development, regulatory and utilization continuum. We envision that the opportunities discussed, and lessons learned from having contrasting perspectives on issues that lack consensus may aid our discipline in more effectively implementing MID3 principles.
| Reference Key |
krishnaswami2020mid3clinical
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Krishnaswami, Sriram;Austin, Daren;Della Pasqua, Oscar;Gastonguay, Marc R;Gobburu, Jogarao;van der Graaf, Piet H;Ouellet, Daniele;Tannenbaum, Stacey;Visser, Sandra A G; |
| Journal | clinical pharmacology and therapeutics |
| Year | 2020 |
| DOI | 10.1002/cpt.1788 |
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.